Pharma

The weight loss drug giants are going in opposite directions

Novo Nordisk invented the modern weight loss drug market with Ozempic. But it's Eli Lilly that is now best positioned to scale that market profitably

ByCatherine Baab

Share to XShare to FacebookShare to RedditShare to EmailShare to Link

Published 12 hours ago|Updated 8 hours ago

Add Quartz on Google

Share to XShare to FacebookShare to RedditShare to EmailShare to Link

Peter Dazeley/Getty Images

It’s a tale of two weight loss drug giants: The best of times for some, the worst for others.

Shares of Novo Nordisk have fallen roughly 17% this week, after the pharma giant forecast a sales drop in 2026. At the same time, Eli Lilly $LLY 10.33% stock was gaining by double digits ahead of Wednesday’s market open, with futures up 8%.

Here's what to........

© Quartz